DPI developer TFF Pharmaceuticals said that is has raised $8.17 million through a Series A preferred stock offering and that it will use the funds for R&D. In April 2018, the company announced that it had raised $14 million for development of inhaled drugs, also through a Series A preferred stock offering. In the past year, TFF has received patents in the … [Read more...] about TFF Pharmaceuticals raises over $8 million, announces executive appointments
News
Acerus Pharmaceuticals licenses intranasal testosterone technology from UT Austin
Acerus Pharmaceuticals said that it has acquired exclusive worldwide rights to technology related to intranasal delivery of testosterone from the University of Texas at Austin. The company said that the agreement covers the use of the intranasal testosterone technology "in all applicable fields." Formerly known as Trimel, Acerus previously developed Natesto … [Read more...] about Acerus Pharmaceuticals licenses intranasal testosterone technology from UT Austin
BlueWillow announces US patent for intranasal anthrax vaccine
According to BlueWillow Biologics, the University of Michigan has been issued US patent No. 10,138,279 which covers an intranasal anthrax vaccine formulated with BlueWillow's NanoVax adjuvant. BlueWillow (formerly NanoBio) is a spin out from the University of Michigan and has an exclusive license to the anthrax vaccine. The company said that its partner … [Read more...] about BlueWillow announces US patent for intranasal anthrax vaccine
Nanoform appoints Miguel Cansado as Director of Project Management
Nanonization company Nanoform has named former Hovione Senior Project Manager Miguel Cansado as Director of Project Management. Cansado is the third former Hovione employee to join Nanoform this year, following the appointments of Miguel Calado as Vice Chairman of the Board and Gonçalo Rebelo de Andrade as Chief of Business Operations. Cansado said, “I am very … [Read more...] about Nanoform appoints Miguel Cansado as Director of Project Management
Particle Sciences gets authorization for manufacturing of Schedule I drugs
CDMO Particle Sciences is now registered with the US Drug Enforcement Administration (DEA) as a manufacturer of Schedule I substances, which means that the company can now provide development and manufacturing services for pharmaceutical cannabinoid products. The company points out that it has long been developing and manufacturing Schedule II-V drugs, including … [Read more...] about Particle Sciences gets authorization for manufacturing of Schedule I drugs
Proveris Scientific adds new IVIVC testing services
Proveris Scientific has announced the availability of new testing services that "support the FDA’s newly released draft guidance on beclomethasone dipropionate that promotes alternate in-vitro studies in lieu of clinical endpoint." According to Proveris, the new services are "Based on an innovative new proprietary technology" and "have been developed in … [Read more...] about Proveris Scientific adds new IVIVC testing services
Insmed raises $250 million in public stock offering
Insmed Incorporated said that a just-closed public stock offering generated net proceeds of about $235.5 million that will be used for continuing commercialization of Arikayce amikacin liposome inhalation suspension (ALIS). The offering of 9,615,385 shares of common stock at $26.00/share resulted in gross proceeds of about $250 million. The underwriters of the … [Read more...] about Insmed raises $250 million in public stock offering
Inhalation Sciences announces plans to validate its PreciseInhale instrument for clinical use
Inhalation Sciences (ISAB) has announced that it will divest 40,000 shares of its subsidiary Ziccum AB in order to finance a study to validate its PreciseInhale dosing system for clinical use. The company said that it anticipates achieving technical and regulatory validation in approximately 15 months. PreciseInhale, which can produce aerosols at a specified dose … [Read more...] about Inhalation Sciences announces plans to validate its PreciseInhale instrument for clinical use
According to Vectura and Sosei, Novartis has filed MAA for triple therapy DPI
Vectura Group and Sosei Group each said that they are owed $2.5 million milestone payments from Novartis after the EU accepted Novartis's MAA for its QVM149 indacaterol/glycopyrronium/mometasone furoate DPI for the treatment of asthma that is inadequately controlled. Vectura said that approval of the MAA would trigger an additional milestone payment of $5 million. … [Read more...] about According to Vectura and Sosei, Novartis has filed MAA for triple therapy DPI
KAER Biotherapeutics gets SBIR grant for development of aerosol therapy for RDS in premature infants
KAER Biotherapeutics has received a $300,000 Small Business Innovation Research (SBIR) grant from the National Heart Lung and Blood Institute of the National Institutes of Health for preclinical development of its SUPRAER aerosol platform for the treatment of surfactant-deficient premature infants with Respiratory Distress Syndrome (nRDS), the company said. The … [Read more...] about KAER Biotherapeutics gets SBIR grant for development of aerosol therapy for RDS in premature infants